Cargando…
Perfusion-Phase [(18)F]THK5351 Tau-PET Imaging as a Surrogate Marker for Neurodegeneration
We aimed to test if early, perfusion phase tau-PET imaging with [(18)F]THK5351 might substitute for [(18)F]FDG PET information on neurodegeneration, as has been previously shown for amyloid-tracers. A patient with cognitive impairment and positive amyloid-PET was examined by [(18)F]THK5351 tau-PET a...
Autores principales: | Brendel, Matthias, Wagner, Leonie, Levin, Johannes, Zach, Christian, Lindner, Simon, Bartenstein, Peter, Okamura, Nobuyuki, Rominger, Axel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159627/ https://www.ncbi.nlm.nih.gov/pubmed/30480233 http://dx.doi.org/10.3233/ADR-170023 |
Ejemplares similares
-
[(18)F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy
por: Brendel, Matthias, et al.
Publicado: (2018) -
Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains
por: Lemoine, Laetitia, et al.
Publicado: (2017) -
Comparison of (18)F-T807 and (18)F-THK5117 PET in a Mouse Model of Tau Pathology
por: Brendel, Matthias, et al.
Publicado: (2018) -
[(18)F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment
por: Jeong, Hye Jin, et al.
Publicado: (2020) -
Neuroimaging-pathological correlations of [(18)F]THK5351 PET in progressive supranuclear palsy
por: Ishiki, Aiko, et al.
Publicado: (2018)